Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 87 clinical trials
Featured trial
C1071003 MagnetisMM-3

The purpose of the study is to evaluate whether single-agent PF-06863135 can provide clinical benefit in participants with relapsed/refractory multiple myeloma. PF-06863135 is a bispecific

refractory multiple myeloma
  • 9 views
  • 25 Nov, 2021
  • 5 locations
None
Daratumumab Pomalidomide and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with daratumumab

immunomodulatory imide drug
pomalidomide
proteasome inhibitor
cancer
thalidomide
  • 0 views
  • 24 Nov, 2021
  • 10 locations
None
Study of SubQ Dara With Dose-Attenuated Bortezomib Lenalidomide Dexamethasone in Elderly NDMM

This is a single center, open-label, phase 2 study in elderly (age 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous

  • 1 views
  • 05 Dec, 2021
  • 1 location
None
Selinexor and Backbone Treatments of Multiple Myeloma Patients

relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: Arm 1: Selinexor + dexamethasone + pomalidomide (SPd)

immunomodulatory imide drug
pomalidomide
elotuzumab
serum proteins
daratumumab
  • 57 views
  • 05 Dec, 2021
  • 24 locations
None
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival

smoldering myeloma
bone marrow procedure
lenalidomide
neutrophil count
bone marrow plasma cells
  • 12 views
  • 28 Nov, 2021
  • 153 locations
None
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute …

refractory multiple myeloma
lenalidomide
measurable disease
dexamethasone
  • 0 views
  • 03 Dec, 2021
  • 26 locations
None
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival

bone marrow procedure
dexamethasone
lenalidomide
neutrophil count
  • 0 views
  • 23 Nov, 2021
  • 92 locations
None
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.

lenalidomide
human chorionic gonadotropin
bortezomib
measurable disease
refractory multiple myeloma
  • 0 views
  • 05 Dec, 2021
  • 30 locations
None
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously

daratumumab
progressive disease
corticosteroids
dexamethasone
maintenance therapy
  • 23 views
  • 05 Dec, 2021
  • 165 locations
None
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To assess the safety and tolerability (including local injection site tolerability) of isatuximab using the (investigational) isatuximab injector device To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute …

pomalidomide
lenalidomide
measurable disease
refractory multiple myeloma
dexamethasone
  • 32 views
  • 02 Dec, 2021
  • 31 locations